1
Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma
Condition(s):Locally Advanced Pancreatic AdenocarcinomaLast Updated:July 27, 2023Recruiting
SD-101: 21 Clinical Trials, Page 1 of 3
Hide Studies Not Open or Pending
2
Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors
Condition(s):Hepatocellular Carcinoma; Intrahepatic CholangiocarcinomaLast Updated:July 27, 2023Recruiting
3
Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma
Condition(s):Metastatic Uveal Melanoma in the LiverLast Updated:January 31, 2023Recruiting
4
SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies
Condition(s):Advanced Malignant Solid Neoplasm; Extracranial Solid Neoplasm; Metastatic Malignant Solid NeoplasmLast Updated:September 15, 2023Completed
5
Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa
Condition(s):Epidermolysis BullosaLast Updated:September 27, 2019Terminated
6
Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis Bullosa
Condition(s):Epidermolysis BullosaLast Updated:November 4, 2019Terminated
7
TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas
Condition(s):B-Cell Non-Hodgkin Lymphoma; Grade 1 Follicular Lymphoma; Grade 2 Follicular Lymphoma; Grade 3a Follicular Lymphoma; Lymphoplasmacytic Lymphoma; Mantle Cell Lymphoma; Marginal Zone Lymphoma; Small Lymphocytic LymphomaLast Updated:May 9, 2022Active, not recruiting
8
ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa
Condition(s):Epidermolysis BullosaLast Updated:April 9, 2020Completed
9
SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer
Condition(s):Metastatic Pancreatic Adenocarcinoma; Refractory Pancreatic Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8Last Updated:August 1, 2023Completed
10
TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma
Condition(s):Grade 1 Follicular Lymphoma; Grade 2 Follicular Lymphoma; Grade 3a Follicular Lymphoma; Recurrent Follicular Lymphoma; Refractory Follicular Lymphoma; Mantle Cell Lymphoma; Marginal Zone LymphomaLast Updated:June 16, 2022Active, not recruiting